Ebola candidate shows promise in international study
The vaccine, ChAd3-EBO-Z, has shown early immunogenicity and acceptability in trials that took place in West Africa, Mali and Baltimore, Maryland. These early studies have also been able to determine the appropriate dosage for large-scale studies and for manufacturing. The research team consists of faculty within the University of Maryland School of Medicine’s Center for Vaccine Development (CVD) and the CVD of Mail, a joint operation between the university and the country’s health ministry.
“This is a crucial step on the road to using this vaccine in humans,” CVD Director Dr. Myron Levine said. “This gives us essential information that the vaccine is not only well-tolerated but the high dose stimulates strong immune responses in adults in West Africa, the global region where the Ebola outbreak was rampant last year.”
In the study, 20 participants in Baltimore and 91 in Mali were given varying doses. The team was able to determine that further studies should be carried out as no safety concerns surfaced over the course of the study.
Should these results be mirrored in large-scale studies and in further clinical trials, the vaccine would be capable of achieving regulatory approval. Researchers state that, if approved, the vaccine candidate would be effective in inhibiting future transmission during potential outbreaks.